Results 91 to 100 of about 3,750,451 (195)

Factfinders for patient safety: Anticoagulant and antiplatelet agents and cervical medial branch procedures. [PDF]

Interv Pain Med, 2022
Lee H, Saffarian M, Babaria V, McCormick ZL, Spine Intervention Society's Patient Safety Committee.   +4 more
europepmc   +1 more source

Efficacy and safety of off-label low-dose compared with standard-dose antiplatelet agents in patients with coronary heart disease: a meta-analysis. [PDF]

Open Heart
Zheng L, Ren Z, Shi Y, Zou J, Hao C, Li Y, Sun L, Wang D, Liu H, Liang S, Zhu B, Li C.   +11 more
europepmc   +1 more source

Preparations from selected cucurbit vegetables as antiplatelet agents. [PDF]

Sci Rep, 2021
Rolnik A, Skalski B, Stochmal A, Olas B.
europepmc   +1 more source

Concerns and recommendations: antiplatelet agents and cancer prevention in non-alcoholic fatty liver disease. [PDF]

Front Oncol
Pham HT, Truong-Nguyen KH, Tran MH.
europepmc   +1 more source

Effects of Oral Anticoagulant and Antiplatelet Agents on Performance of Multitarget Colorectal Cancer Screening Test. [PDF]

Gastro Hep Adv
Coombs RA, Adkins JL, Turunen AM, Salfiti NI, Khanna S, Garg SK.   +5 more
europepmc   +1 more source

Opioid Overdose in Patients With Concomitant Use of Tramadol and Clopidogrel vs Alternative Antiplatelet Agents. [PDF]

J Am Coll Cardiol
Bea S, Huybrechts KF, Edrees HH, Basham CA, Vine SM, Glynn RJ, Bateman BT, Bykov K.   +7 more
europepmc   +1 more source

Contribution of Helicobacter pylori infection to the risk of peptic ulcer bleeding in patients on nonsteroidal anti‐inflammatory drugs, antiplatelet agents, anticoagulants, corticosteroids and selective serotonin reuptake inhibitors

Alimentary Pharmacology and Therapeutics, 2018
M. Venerito, C. Schneider, R. Costanzo, R. Breja, F. Röhl, P. Malfertheiner   +5 more
semanticscholar   +1 more source

How to undertake procedures while on antiplatelet agents: a hematologist's view. [PDF]

Res Pract Thromb Haemost
Swan D, Turner R, Douketis J, Thachil J.
europepmc   +1 more source

Platelet Glycoprotein-Ib (GPIb) May Serve as a Bridge between Type 2 Diabetes Mellitus (T2DM) and Atherosclerosis, Making It a Potential Target for Antiplatelet Agents in T2DM Patients. [PDF]

Life (Basel), 2023
Amalia M, Puteri MU, Saputri FC, Sauriasari R, Widyantoro B.   +4 more
europepmc   +1 more source

Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis.

Journal of the American College of Cardiology, 2017
C. Patrono, J. Morais, C. Baigent, J. Collet, D. Fitzgerald, S. Halvorsen, B. Rocca, A. Siegbahn, R. Storey, G. Vilahur   +9 more
semanticscholar   +1 more source